JP2018532789A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018532789A5 JP2018532789A5 JP2018541592A JP2018541592A JP2018532789A5 JP 2018532789 A5 JP2018532789 A5 JP 2018532789A5 JP 2018541592 A JP2018541592 A JP 2018541592A JP 2018541592 A JP2018541592 A JP 2018541592A JP 2018532789 A5 JP2018532789 A5 JP 2018532789A5
- Authority
- JP
- Japan
- Prior art keywords
- migraine
- methyl
- oxo
- composition
- diazaspiro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 12
- -1 7-Methyl-1H-indazol-5-yl Chemical group 0.000 claims 11
- 206010027599 migraine Diseases 0.000 claims 8
- 208000019695 Migraine disease Diseases 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 208000000060 Migraine with aura Diseases 0.000 claims 2
- 206010047700 Vomiting Diseases 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 230000009245 menopause Effects 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 230000001314 paroxysmal effect Effects 0.000 claims 2
- 230000000737 periodic effect Effects 0.000 claims 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 230000008673 vomiting Effects 0.000 claims 2
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 206010049714 Abdominal migraine Diseases 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 206010050258 Basilar migraine Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000006561 Cluster Headache Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010014020 Ear pain Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000033830 Hot Flashes Diseases 0.000 claims 1
- 206010060800 Hot flush Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010033078 Otitis media Diseases 0.000 claims 1
- 206010052784 Retinal migraine Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 241001303601 Rosacea Species 0.000 claims 1
- 206010042496 Sunburn Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 208000018912 cluster headache syndrome Diseases 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000035238 familial hemiplegic 1 migraine Diseases 0.000 claims 1
- 206010067039 familial hemiplegic migraine Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 230000002175 menstrual effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000017420 migraine with brainstem aura Diseases 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000004700 rosacea Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000006122 sporadic hemiplegic migraine Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1519195.0 | 2015-10-30 | ||
| GBGB1519195.0A GB201519195D0 (en) | 2015-10-30 | 2015-10-30 | CGRP Receptor Antagonists |
| PCT/IB2016/056518 WO2017072722A1 (en) | 2015-10-30 | 2016-10-28 | Cgrp receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018532789A JP2018532789A (ja) | 2018-11-08 |
| JP2018532789A5 true JP2018532789A5 (enExample) | 2019-12-05 |
| JP6874013B2 JP6874013B2 (ja) | 2021-05-19 |
Family
ID=55130447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018541592A Active JP6874013B2 (ja) | 2015-10-30 | 2016-10-28 | Ｃｇｒｐ受容体アンタゴニスト |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9802935B2 (enExample) |
| EP (1) | EP3368536B1 (enExample) |
| JP (1) | JP6874013B2 (enExample) |
| CN (1) | CN108431005B (enExample) |
| AR (1) | AR106488A1 (enExample) |
| AU (1) | AU2016344688A1 (enExample) |
| BR (1) | BR112018008419A2 (enExample) |
| CA (1) | CA3002623A1 (enExample) |
| GB (1) | GB201519195D0 (enExample) |
| IL (1) | IL258893A (enExample) |
| SG (1) | SG11201803380RA (enExample) |
| TW (1) | TW201722952A (enExample) |
| WO (1) | WO2017072722A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201519196D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| GB201519195D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| GB201908430D0 (en) | 2019-06-12 | 2019-07-24 | Heptares Therapeutics Ltd | Cgrp antagonist compounds |
| GB201908420D0 (en) | 2019-06-12 | 2019-07-24 | Heptares Therapeutics Ltd | Cgrp antagonist compounds |
| CN116806150A (zh) * | 2021-01-05 | 2023-09-26 | 载度思生命科学有限公司 | 新的自分泌运动因子抑制剂 |
| CA3250924A1 (en) * | 2022-04-29 | 2025-07-09 | Brise Pharmaceuticals Co., Ltd. | Piperidine carboxamide azaindane derivative, its preparation process and use |
| CN117624191A (zh) * | 2022-08-30 | 2024-03-01 | 熙源安健医药（上海）有限公司 | 吲唑甲酰胺类衍生物及其制备方法和用途 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2732221B1 (fr) | 1995-03-28 | 1997-04-25 | Oreal | Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue |
| ATE266673T1 (de) | 1996-09-10 | 2004-05-15 | Boehringer Ingelheim Pharma | Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| US20030069231A1 (en) | 1999-10-12 | 2003-04-10 | Klaus Rudolf | Modified aminoacids, pharmaceuticals containing these compounds and method for their production |
| US6294534B1 (en) | 1998-06-11 | 2001-09-25 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
| AU742425B2 (en) | 1998-06-11 | 2002-01-03 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
| US7842808B2 (en) | 2002-06-05 | 2010-11-30 | Bristol-Myers Squibb Company | Anti-migraine spirocycles |
| LT1539766T (lt) * | 2002-06-05 | 2017-03-10 | Bristol-Myers Squibb Company | Su kalcitonino genu susijusio peptido receptoriaus antagonistai |
| US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
| US7202251B2 (en) * | 2003-03-14 | 2007-04-10 | Merck & Co., Inc. | Bicyclic anilide spirohydantoin CGRP receptor antagonists |
| JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
| AU2003297694A1 (en) | 2003-12-05 | 2005-08-12 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
| TW200524601A (en) | 2003-12-05 | 2005-08-01 | Bristol Myers Squibb Co | Heterocyclic anti-migraine agents |
| TW200533398A (en) | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
| DE102004015723A1 (de) | 2004-03-29 | 2005-10-20 | Boehringer Ingelheim Pharma | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| US20050233980A1 (en) | 2004-04-20 | 2005-10-20 | Boehringer Ingelheim International Gmbh | CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine |
| DE102004019492A1 (de) | 2004-04-22 | 2005-11-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| WO2006006490A1 (ja) * | 2004-07-08 | 2006-01-19 | Ono Pharmaceutical Co., Ltd. | スピロ化合物 |
| JP4913061B2 (ja) | 2004-10-13 | 2012-04-11 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｃｇｒｐ受容体拮抗薬 |
| US7732438B2 (en) | 2004-10-14 | 2010-06-08 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists |
| CN101068595A (zh) | 2004-10-22 | 2007-11-07 | 默克公司 | Cgrp受体拮抗剂 |
| EP1770091A1 (de) | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| US7834007B2 (en) | 2005-08-25 | 2010-11-16 | Bristol-Myers Squibb Company | CGRP antagonists |
| EP2029234A1 (en) | 2006-06-08 | 2009-03-04 | Boehringer Ingelheim International GmbH | Treatment of gastrointestinal disorders with cgrp-antagonists |
| CA2705405A1 (en) * | 2007-11-22 | 2009-05-28 | Boehringer Ingelheim International Gmbh | New compounds |
| US8044043B2 (en) | 2008-04-11 | 2011-10-25 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| TW201031665A (en) * | 2009-02-04 | 2010-09-01 | Gruenenthal Gmbh | Substituted indole-compound |
| US8314117B2 (en) | 2009-10-14 | 2012-11-20 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| US8481546B2 (en) | 2010-03-30 | 2013-07-09 | Bristol-Myers Squibb Company | CGRP receptor antagonist |
| US9174989B2 (en) | 2012-05-09 | 2015-11-03 | Merck Sharp & Dohme Corp. | Process for making CGRP receptor antagonists |
| GB201519195D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| GB201519194D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP receptor antagonists |
| GB201519196D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
-
2015
- 2015-10-30 GB GBGB1519195.0A patent/GB201519195D0/en not_active Ceased
-
2016
- 2016-10-28 US US15/336,880 patent/US9802935B2/en active Active
- 2016-10-28 AR ARP160103295A patent/AR106488A1/es unknown
- 2016-10-28 JP JP2018541592A patent/JP6874013B2/ja active Active
- 2016-10-28 EP EP16791444.9A patent/EP3368536B1/en active Active
- 2016-10-28 AU AU2016344688A patent/AU2016344688A1/en not_active Abandoned
- 2016-10-28 TW TW105135023A patent/TW201722952A/zh unknown
- 2016-10-28 CN CN201680063997.2A patent/CN108431005B/zh active Active
- 2016-10-28 SG SG11201803380RA patent/SG11201803380RA/en unknown
- 2016-10-28 WO PCT/IB2016/056518 patent/WO2017072722A1/en not_active Ceased
- 2016-10-28 CA CA3002623A patent/CA3002623A1/en not_active Abandoned
- 2016-10-28 BR BR112018008419A patent/BR112018008419A2/pt not_active Application Discontinuation
-
2017
- 2017-09-19 US US15/708,424 patent/US10259812B2/en active Active
-
2018
- 2018-04-24 IL IL258893A patent/IL258893A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018532789A5 (enExample) | ||
| JP2018532788A5 (enExample) | ||
| JP7756643B2 (ja) | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 | |
| JP2016516791A5 (enExample) | ||
| WO2019027858A1 (en) | BENZO [B] STING THIOPHEN AGONISTS FOR THE TREATMENT OF CANCER | |
| JP2014513110A5 (enExample) | ||
| TW201011021A (en) | Imidazopyridin-2-one derivative | |
| JP2023540673A (ja) | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 | |
| JP2017523152A5 (enExample) | ||
| JP2016525075A5 (enExample) | ||
| RU2015104537A (ru) | Способы лечения стромальных опухолей желудочно-кишечного тракта | |
| JP2016525076A5 (enExample) | ||
| JP2013512953A5 (enExample) | ||
| RU2018120318A (ru) | ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА | |
| JP2015512398A5 (enExample) | ||
| RU2018120492A (ru) | ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА | |
| JP2023540672A (ja) | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 | |
| WO2019136244A1 (en) | Heterocyclic compounds for the treatment of abnormal cellular proliferation | |
| JP2023505877A (ja) | インターフェロン遺伝子刺激因子（ｓｔｉｎｇ）のモジュレーターとしての官能化した複素環式化合物 | |
| KR20180013850A (ko) | 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린의 용도 | |
| AU2021403015A1 (en) | Multi-cyclic irak and flt3 inhibiting compounds and uses thereof | |
| JP2023540674A (ja) | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 | |
| EP4188926A1 (en) | Multi-cyclic irak and flt3 inhibiting compounds and uses thereof | |
| JP2023505878A (ja) | インターフェロン遺伝子刺激因子（ｓｔｉｎｇ）のモジュレーターとしての複素環式化合物 | |
| JP2018532790A5 (enExample) |